US Endovascular
US Endovascular distributes coronary and peripheral vascular medical devices directly to outpatient labs, ambulatory surgery centers, and hospitals via an account-gated e-commerce platform, sourcing from manufacturers to cut supply chain intermediaries. Headquartered in St. Louis and operating in the United States.
- Company typePrivate
- Founded2014
- HeadquartersSt Louis, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What US Endovascular does
US Endovascular, LLC is a privately held US medical device distributor founded in 2014 and headquartered in St. Louis, Missouri. The company specializes in coronary and peripheral vascular devices sold directly to outpatient catheterization labs (OBLs), ambulatory surgery centers (ASCs), and hospitals through an account-gated e-commerce storefront. Its operating premise is supply chain disintermediation: by sourcing directly from manufacturers and shipping via FedEx, it claims to deliver next-generation devices at the lowest available prices versus traditional multi-tier distribution. The product portfolio spans PTA balloon catheters (Achilles, Castor, Polux, Atropos, TICHE HP, and Parafleet sub-brands), the Revolution™ peripheral atherectomy device, the EluNIR PERL drug-eluting stent, peripheral guide wires, introducer sheath kits, 30atm inflation devices, the SuperClip™ securement clasp (covered by US Pat. No. 9,127,786), and StatGuard hemostatic dressings.
Through an August 2024 strategic partnership with Innovative Health, US Endovascular operates the RePRO program, offering FDA-cleared reprocessed single-use devices — including Philips IVUS catheters — either for purchase at discount or in exchange for credit on returned devices. Pricing is account-based, gated behind account creation, and primarily per-unit with bulk packaging (boxes of 5 or 10). Revenue derives entirely from hardware sales; no software, subscription, or service-fee revenue stream is disclosed. The company has no disclosed funding rounds, no parent company, no subsidiaries, and headcount listed at 1-10 employees.
Leadership consists of President/CEO John McCurdy (joined 2014, prior roles at Cardiva Medical, Neothermia/Intact Medical, Guidant), COO/CFO John Vacha (joined 2016, former President & CEO of Intact Medical prior to its Medtronic acquisition), founding member David Gardner, and Marketing Director Aris McCurdy. Operating geographies are limited to the United States with stated Midwest concentration; international markets are explicitly not served. The company holds one registered US patent (SuperClip, US Pat. No. 9,127,786) and discloses no regulatory actions, mergers, acquisitions, or restructuring events.
US Endovascular firmographics
Firmographics- Name
- US Endovascular
- Legal name
- US Endovascular, LLC
- Website
- https://usendovascular.net
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- US Endovascular distributes coronary and peripheral vascular medical devices directly to outpatient labs, ambulatory surgery centers, and hospitals via an account-gated e-commerce platform, sourcing from manufacturers to cut supply chain intermediaries. Headquartered in St. Louis and operating in the United States.
- Ownership category
- akta.pro rank
US Endovascular industry classification
Industry- Product category
- Vascular Medical Device Distribution
- NAICS
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)
- akta.pro secondary industries
- Coronary Stents & Drug-Eluting Technologies (HLAHAFAA), Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ), Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)
Keywords
Where US Endovascular is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
US Endovascular business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: US Endovascular generates revenue through the direct sale of coronary and peripheral vascular medical devices to outpatient labs, surgery centers, and hospitals. They purchase directly from manufacturers and distribute to end users, cutting out intermediaries in the supply chain.
- Reprocessed Device Sales: Sale of FDA-cleared reprocessed single-use medical devices including Philips IVUS catheters through the RePRO partnership with Innovative Health, providing discounted alternatives to new devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Account-based pricing with volume discounts |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
US Endovascular product offering
Product offeringCore offering
US Endovascular purchases coronary and peripheral vascular medical devices directly from manufacturers and resells them to outpatient catheterization labs (OBLs), ambulatory surgery centers (ASCs), and hospitals through an account-gated e-commerce storefront. By eliminating distributor intermediaries in the supply chain, the company offers next-generation angioplasty balloons, atherectomy devices, drug-eluting stents, IVUS catheters, guide wires, sheath kits, and accessory devices at reduced prices, complemented by the RePRO single-use device reprocessing program offered in partnership with Innovative Health.
Product overview
US Endovascular is a medical device distributor specializing in coronary and peripheral vascular devices for outpatient labs (OBLs), surgery centers (ASCs), and hospitals. The company operates on a direct-from-manufacturer business model to reduce supply chain costs. The product portfolio is organized around several core device categories: PTA balloon catheters (including Achilles, Castor, Polux, Atropos, TICHE, and Parafleet sub-brands), the Revolution™ peripheral atherectomy device with front-cutting technology, EluNIR PERL drug eluting stents, Philips reprocessed IVUS catheters (via Innovative Health partnership), high-pressure inflation devices, peripheral guide wires, introducer sheath kits, hemostatic patches (StatGuard), and guidewire securement devices (SuperClip). Additional services include the RePRO program for reprocessed device recycling and cost savings.
Differentiator
Problem solved
Functional benefit
Brands
- RePRO: Reprocessing program offered in partnership with Innovative Health, allowing customers to purchase or donate reprocessed single-use medical devices including Philips IVUS catheters and atherectomy devices.
Products and services
- PTA Balloon Catheters Percutaneous Transluminal Angioplasty (PTA) balloon catheters for vascular interventions, including non-compliant sub-brands Achilles and Castor, semi-compliant/ultra low-profile Polux, and semi-compliant Atropos, available in .014, .018, and .035 inch profiles. Sold to OBLs, ASCs, and hospitals.
- TICHE High Pressure .035 PTA Balloon High-pressure non-compliant .035 inch PTA balloon catheter designed for challenging lesions requiring higher inflation pressures.
- Parafleet Tapered .014 Peripheral Balloons Tapered peripheral angioplasty balloon catheters with .014 inch profile, designed for peripheral vascular interventions.
- Philips Reprocessed IVUS Catheters
Quantifiable outcome
- Significant cost reduction through supply chain optimization
- +1 more outcomes
Companies that use US Endovascular
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
US Endovascular technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
US Endovascular partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Innovative Health LLCcoreUS Endovascular partnered with Innovative Health to offer the RePRO program, providing customers significant savings on reprocessed single-use medical devices. The partnership allows facilities to become Purchasing Customers (buying reprocessed devices at discounted rates) or Donor Customers (donating used devices for money or discounts). The program covers Philips IVUS catheters and atherectomy devices.
Scale indicators2 records
Recent moves4 records
Expansion highlights4 records
US Endovascular competitors and assessment
Company assessmentBroad incumbents
- Boston Scientific: Boston Scientific's Peripheral Interventions and Interventional Cardiology businesses sell stents, PTA balloons, atherectomy, and access devices that directly overlap US Endovascular's product lines, with substantially greater scale and physician relationships.
- Penumbra: Penumbra is a leading interventional thrombectomy and peripheral vascular device company with a broad product portfolio that overlaps USE's peripheral atherectomy/thrombectomy focus (Revolution is dual-indicated for both). Comparable as a specialist in catheter-based vascular intervention competing for the same OBL/ASC accounts.
- Philips (Image-Guided Therapy): Philips manufactures the IVUS catheters that USE resells (reprocessed) under the RePRO program. Philips competes in the same intravascular imaging/therapy category and is a key OEM partner that could bypass USE if commercial priorities change.
- Medtronic: Medtronic is a global leader in coronary and peripheral vascular intervention (stents, balloons, atherectomy, guidewires, sheaths) and acquired Intact Medical, where USE's COO previously served. It competes head-on with USE in the same hospital and ASC accounts with much deeper clinical evidence and sales coverage.
- Abbott Vascular: Abbott (including the former Cardiovascular Systems Inc. business, where USE's founder previously worked) markets coronary stents, peripheral atherectomy, and other vascular devices that compete with USE's portfolio across the same OBL/ASC and hospital customers.
- Medline Industries: Medline is one of the largest privately held medical supply manufacturers and distributors in the US, serving hospitals, surgery centers, and OBLs with a broad portfolio that overlaps USE's peripheral and coronary device catalog. It is a relevant incumbent comparable for distribution model and end customers.
- Cardinal Health: Cardinal Health is one of the largest US medical device and supply distributors, supplying hospitals, ASCs, and physician offices. It is the type of broad-line distributor against which USE's disintermediated direct-to-manufacturer model competes for the same B2B customers.
- McKesson Medical-Surgical: McKesson Medical-Surgical is a national medical equipment and supplies wholesaler serving physician offices, surgery centers, and hospitals. It is a direct comparator on distribution model and target customer base, but at vastly greater scale and with broader catalog.
Direct peers
- Innovative Health: Innovative Health is US Endovascular's reprocessing partner and operates a directly comparable single-use device reprocessing model (including Philips IVUS and atherectomy catheters). They share the same specialty cardiovascular reprocessing economics and overlapping customer base at OBLs/ASCs.
- Rex Medical: Rex Medical is the manufacturer of USE's flagship Revolution peripheral atherectomy device. As the OEM partner, Rex Medical is highly comparable to USE on the device side and is the upstream counterpart of USE's distribution business in atherectomy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
US Endovascular social profiles
Digital presenceUS Endovascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
US Endovascular leadership team
Management profileNumber of profiles
Profiles4 records
US Endovascular funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
US Endovascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about US Endovascular
What does US Endovascular do?
US Endovascular purchases coronary and peripheral vascular medical devices directly from manufacturers and resells them to outpatient catheterization labs (OBLs), ambulatory surgery centers (ASCs), and hospitals through an account-gated e-commerce storefront. By eliminating distributor intermediaries in the supply chain, the company offers next-generation angioplasty balloons, atherectomy devices, drug-eluting stents, IVUS catheters, guide wires, sheath kits, and accessory devices at reduced prices, complemented by the RePRO single-use device reprocessing program offered in partnership with Innovative Health.
Is US Endovascular a public or private company?
US Endovascular is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was US Endovascular founded?
US Endovascular was founded in 2014. It employs 1 to 10 people.
Where is US Endovascular based?
US Endovascular is headquartered in St Louis, United States, in the North America region.
How does US Endovascular make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are reprocessed Device Sales.
Who are US Endovascular's main competitors?
Broad incumbents on record are Boston Scientific, Penumbra, Philips (Image-Guided Therapy), Medtronic, Abbott Vascular, Medline Industries, Cardinal Health and McKesson Medical-Surgical. Direct peers are Innovative Health and Rex Medical.
Does US Endovascular have an API?
No public API is recorded for US Endovascular.
What industry is US Endovascular in?
US Endovascular's product category is Vascular Medical Device Distribution. Its primary akta.pro industry code is HLAHAFAK, Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems), with a secondary code of HLAHAFAA, Coronary Stents & Drug-Eluting Technologies. Its NAICS code is 42345 and its SIC code is 3841.